April 25th 2024
The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.
The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.
April 24th 2024
Deal gives Incyte access to Escient’s pipeline of oral MRGPR antagonists, including EP262 and EP547.
April 16th 2024
Company also purchased equipment for 12 good manufacturing practice clean rooms.
Capital also expected to assist the advancement of Evergreen's radiopharmaceutical discovery pipeline into clinical trials.
HDMA Annual Factbook: Primary Healthcare Distributors Handle 85% of Prescription Drug Sales
Annual compilation tracks evolution of wholesaler services, adoption of new technologies
Industry Mergers Reshuffle Animal-Health Leadership
With sales of human pharmaceuticals languishing, several factors are focusing increased attention on animal health products, once a little-noticed industry niche market
PHRMA, Foundations Establish 'Medical Homes' in New Jersey
Program seeks to improve the economics of care for low-income families; more sites to come
The Business Value of Brand Protection
Specific, technology-based anticounterfeiting measures are a tactical response to a strategic problem. Holistic prevention strategies are needed
NACDS Annual Profile Tracks Declining Number of Stores
At 28% pharmaceutical sales, chain pharmacy still represents the single largest channel for delivering prescriptions to patients
Changing the Channel: Developments in US Specialty Pharmaceutical Distribution
AmerisourceBergen Keeps a Focus on Independent Pharmacy
Coming off a record-setting year, ABC stresses growth in generics, and services revolving around specialty pharmaceuticals
Challenges in Contract Strategy and Operations for Pharmaceutical Manufacturers
Effective integration of a company’s contract strategy with operations can have a big impact on financial performance
2009 Medco Drug Trend Report: Specialty Medications Begin to Drive Spending
While drug spending by clients averaged 3.3% last year, higher spending growth is predicted for the next three years
Global Pharma Sales Growth Will Flatten to 2.5-3.5% in 2009
US market will enter negative growth this year, says IMS Health
Riding the Biotech Financing Rollercoaster
Fine-Tuning Specialty Distribution
Specialty manufacturers have a range of options to consider in how to go to market
A Data-Driven Approach to Contract Performance Monitoring and Analysis
Better use of available data can add rigor to analyzing managed-markets contracts, thereby allocating rebates / discounts more effectively
2008 Market Summary From IMS Health: US Pharma Sales Up 1.3%, the Lowest in Decades
US total reaches $291.5 billion; dispensed prescriptions up 0.9%
McKesson Jumps Into Plasma, Blood-Based Products Wholesaling
New unit will ship from La Vergne, TN specialty-care products warehouse
Armada Gathers 1,000 Attendees at its 5th Specialty Pharmacy Summit
Specialty GPO is doubling attendance year-over-year
Stem Cell Therapy: Business Models Begin to Take Shape
Although human trials in the U.S. are still a novelty, developers are identifying both sources and protocols for conducting therapy
Independent Pharmacies Promote the Value of Their Patient Contact to the Pharma Industry
Although beset by less-than-friendly federal reimbursement policies, independent pharmacies are maintaining their viability for pharmaceutical delivery
Long-Term Drug Approval Trends Highlight the Industry's Productivity Dilemma
Higher complexity—and expense—are the reality for most drug research, says Tufts
Novartis Managed Care Report Finds Higher Barriers to Drug Access
Higher co-pays, ‘NDC block policies’ and multiple tiers add to drug benefit complexity
Examining the ROI of personalized medicine
New Deloitte study finds “profound” positive and negative ROIs for combined therapies and diagnostics based on genetics